Paid Clinical Trials and Focus Groups by Location |
|
|
|
Conditions: Fluid Therapy; Water Electrolyte Imbalance; Acid Base Imbalance
Interventions: Drug: Crystalloid; Drug: Colloid
Sponsor: University of Nottingham
Not yet recruiting - verified March 2010
Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: NN9925 (oral); Drug: NN9925 (i.v.); Drug: placebo; Drug: NN9925 (oral); Drug: placebo
Sponsor: Novo Nordisk
Not yet recruiting - verified March 2010
Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010
Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Condition: Psoriasis
Interventions: Drug: Ustekinumab/Methotrexate; Drug: Ustekinumab/Methotrexate
Sponsor: Janssen-Cilag International NV
Recruiting - verified February 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin; Drug: Glimepiride
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Insulin aspart; Drug: Insulin Glulisine
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hyperparathyroidism, Primary
Intervention:
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Follicular Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Daclizumab HYP; Drug: Daclizumab HYP
Sponsors: Biogen Idec; Facet Biotech
Recruiting - verified March 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: pazopanib and pemetrexed; Drug: pemetrexed and cisplatin
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Metastatic; Colorectal Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified February 2010
Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease
Interventions: Drug: Cinacalcet; Drug: Vitamin D
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Condition: Myocardial Infarction
Interventions: Drug: tenecteplase; Drug: enoxaparin; Drug: clopidogrel; Procedure: catheterisation; Procedure: primary PCI
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Xeloda
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Mitral Regurgitation; Coronary Artery Disease
Interventions: Procedure: Mitral annuloplasty; Procedure: Coronary Artery Bypass Graft Surgery
Sponsors: Imperial College London; Department of Health, United Kingdom; British Heart Foundation; British Medical Association; Hammersmith Hospitals NHS Trust; St Mary's NHS Trust; King's College Hospital NHS Trust; Glasgow Royal Infirmary; Golden Jubilee National Hospital; University Hospitals, Leicester; Nottingham University Hospitals NHS Trust; Medical University of Silesia; Papworth Hospital; Central Manchester University Hospitals NHS Foundation Trust; United Bristol Healthcare NHS Trust; Blackpool, Flyde and Wyre Hospitals NHS Foundation Trust; Oxford Radcliffe Hospitals NHS Trust
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Glioma; Medulloblastoma
Interventions: Drug: Irinotecan; Drug: Temozolomide
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsor: Southampton University Hospitals NHS Trust
Recruiting - verified March 2008
Condition: Endocrine Tumors
Interventions: Drug: lanreotide (Autogel formulation); Other: Placebo
Sponsor: Ipsen
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
All Locations ... United Kingdom » ... England » ... Nottingham 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
